Celldex Therapeutics, Inc.
About Celldex Therapeutics, Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.5M
- Net income
- -$258.8M
- Total assets
- $583.0M
- Market cap
- $2.2B
- Gross margin
- 87.1%
- Operating margin
- -18599.8%
- Net margin
- -16748.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.5M
- Cost of revenue
- $200.0K
- Gross profit
- $1.3M
- Operating expenses
- $288.7M
- Operating income
- -$287.4M
- Income tax
- $0
- Net income
- -$258.8M
- EPS (basic)
- $-3.90
- EPS (diluted)
- $-3.90
Balance sheet
- Total assets
- $583.0M
- Current assets
- $534.7M
- Total liabilities
- $55.8M
- Current liabilities
- $51.0M
- Shareholders’ equity
- $527.2M
Cash flow
- Operating cash flow
- -$210.9M
- Investing cash flow
- $209.1M
- Financing cash flow
- $2.4M
- Net cash flow
- $515.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.2B
- EPS (diluted)
- $-3.9
- Shares outstanding
- 78.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 15, 1986
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $258.8M in FY2025.
- Revenue declined 67% from FY2021 to FY2025.
- Gross margin of 87.1%, net margin -16748.0%.
- Trading 17% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Celldex Therapeutics, Inc..
Write a review
News about Celldex Therapeutics, Inc.
News & sentiment via Polygon.io
